We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
- Authors
Nagai, Hirokazu; Yano, Takahiro; Watanabe, Tomoyuki; Uike, Naokuni; Okamura, Seiichi; Hanada, Shuichi; Kawano, Fumio; Sunami, Kazutaka; Inoue, Nobumasa; Sawamura, Morio; Nishiura, Tetsuo; Hotta, Tomomitsu; Horibe, Keizo
- Abstract
Many controlled clinical trials have proven that rituximab improves the clinical outcome of patients with mature B cell lymphoma. This study was conducted to assess the contribution of rituximab in the actual clinical practice. Patients with newly diagnosed mature B cell lymphoma treated at 20 National Hospital Organization hospitals from January 2000 to December 2004 were consecutively registered. Rituximab was approved in September 2002 for indolent B cell lymphoma and in September 2003 for aggressive B cell lymphoma in Japan. The patients were divided into two groups depending on whether they received induction therapy containing rituximab. The endpoint was to evaluate the rituximab benefit based on 2-year progression-free survival (PFS) and 2-year overall survival (OS). A total 1126 patients received chemotherapies. Of these, 762 were diagnosed as diffuse large B cell lymphoma (DLBCL) and 215 as follicular lymphoma (FL). PFS and OS were markedly improved in the rituximab group compared with the non-rituximab group in patients with DLBCL (both P < 0·001) and in patients with FL ( P < 0·001 and P = 0·003 respectively). Rituximab, when used for remission induction therapy, significantly improved the clinical outcome of the mature B cell lymphoma patient in actual clinical practice.
- Subjects
CLINICAL trials; RITUXIMAB; B cells; LYMPHOMAS; THERAPEUTICS; CLINICAL medicine
- Publication
British Journal of Haematology, 2008, Vol 143, Issue 5, p672
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/j.1365-2141.2008.07390.x